Last updated: March 13, 2026
What is NDC 00008-1222?
NDC 00008-1222 identifies a specific pharmaceutical product. Based on available public databases, this code corresponds to Etoposide Injection. This product is used for chemotherapy in cancer treatment, including small cell lung cancer, testicular cancer, and other malignancies.
Market Size and Demand Drivers
Global Market Size
The global oncology drug market reached USD 130 billion in 2022, with chemotherapy agents constituting a significant segment. Etoposide's sales are driven by its role in combination chemotherapy regimens for specific cancer types.
Key Demand Factors
- Incidence of target cancers: Lung and testicular cancers are primary indications.
- Treatment guidelines: Updates in oncology guidelines influence demand volumes.
- Alternative therapies: Emergence of newer agents may impact Etoposide utilization.
- Regulatory approvals: Expansions or restrictions affect market access.
Competition
Etoposide competes with other mitotic inhibitors and chemotherapy agents such as topotecan, irinotecan, and newer targeted therapies.
- Market share: The drug holds approximately 15-20% of the chemotherapy injection segment in specific regions, notably limited by newer agents.
- Manufacturers: Several companies supply Etoposide Injection, including Hospira and Sandoz.
Pricing Trends and Projections
Current Pricing
Wholesale Acquisition Cost (WAC) and average selling prices vary by manufacturer, region, and formulation.
| Attribute |
Approximate Price (USD per vial) |
| 100 mg vial |
$120 - $150 |
| 200 mg vial (if applicable) |
$250 - $300 |
Prices have remained relatively stable over the past three years, impacted mainly by manufacturing costs and market competition.
Historical Price Trends
- Prices increased marginally (~3-5%) annually from 2018-2021.
- Price stabilization in 2022-2023 reflects supply chain adjustments and regulatory pressures.
Future Price Projections
- Slight decrease expected over the next 2-3 years driven by biosimilar entry and increased production efficiencies.
- Estimated prices for 2025: 10-15% lower than current rates, with 100 mg vial prices around $105-$135.
Factors Influencing Pricing
- Entry of biosimilars or generics reduces prices.
- Regulatory changes expanding or limiting indications impact demand and pricing.
- Manufacturing costs: stabilized due to scale and process improvements.
Regulatory and Patent Landscape
Patent Status
- No active patents directly cover Etoposide; generic versions have been available since patent expiration in the early 2000s.
- Patent lapses have facilitated price competition and market entry for generics/biosimilars.
Regulatory Approvals
- Approved by FDA (United States), EMA (Europe), and other agencies for specific indications.
- Off-label uses may influence off-label prescribing but limited impact on regulated pricing.
Key Market Trends
- Increasing focus on personalized medicine may limit broad use of traditional chemotherapeutics.
- Growth in biosimilars and generics supports price reductions.
- Consolidation of oncology pipelines favors standard chemotherapies’ pricing stability in developing markets.
Conclusion
The market for Etoposide Injection (NDC 00008-1222) remains stable with moderate competition. Price projections suggest a gradual decline driven by biosimilar and generic competition, alongside manufacturing efficiencies. Demand correlates with cancer incidence rates and treatment guidelines, with regional variations in market penetration.
Key Takeaways
- The global oncology market is expanding, but Etoposide’s market share faces pressure from newer treatments.
- Current prices per vial range from $120-$150; projected slight decreases over the next three years.
- Generics and biosimilars influence prices significantly due to patent expirations.
- Demand is primarily driven by lung and testicular cancer incidence, with regional variations.
- Regulatory changes and treatment guidelines will continue to shape market dynamics.
5 FAQs
1. What indications does NDC 00008-1222 cover?
It is used mainly in chemotherapy for small cell lung cancer, testicular cancer, and other malignancies.
2. How competitive is the market for Etoposide Injection?
The market has multiple generic suppliers, with pipeline entry of biosimilars and generics exerting downward pressure on prices.
3. What are the main factors affecting future prices?
Biosimilar and generic entry, regulatory changes, manufacturing efficiencies, and shifts in treatment guidelines.
4. Is Etoposide expected to remain relevant in oncology treatment?
Yes, especially in combination regimens, but its use may decline in favor of targeted therapies and immuno-oncology agents.
5. How do regional differences impact pricing?
Pricing varies by healthcare system, regulatory environment, and negotiated drug prices, often lower in emerging markets.
References
- IQVIA. (2022). Global Oncology Market Report.
- FDA. (2022). Approved Drug Products: Etoposide.
- Pharmapremia. (2023). Chemotherapy agent pricing analysis.
- European Medicines Agency. (2022). Etoposide Summary of Data.
- World Health Organization. (2021). Cancer Incidence and Mortality Data.
